Barry E. Greene - 16 Jan 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
President and CEO, Director
Signature
Brandon Marsh, attorney in fact for GREENE BARRY E.
Issuer symbol
SAGE
Transactions as of
16 Jan 2025
Net transactions value
$0
Form type
4
Filing time
21 Jan 2025, 16:11:46 UTC
Previous filing
07 Aug 2024
Next filing
11 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +174,000 $0.000000 174,000 16 Jan 2025 Common Stock 174,000 $6.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 43,500 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 130,500 shares vesting in 36 equal monthly installments thereafter.